Market Overview

UPDATE: Citigroup Raises PT on IPC The Hospitalist Company Following 2Q13 EPS Report

Share:

In a report published Monday, Citigroup analyst Robin Shoemaker reiterated a Buy rating on IPC The Hospitalist Company (NASDAQ: IPCM), and raised the price target from $68.00 to $70.00.

In the report, Citigroup noted, “DRC reported 2Q13 EPS of $0.69 compared to our $0.57 estimate and the $0.57 consensus. Revenues of $805M were well below our $845M estimate and the $837M consensus estimate. Full-year 2013 operating income guidance was lowered to $430M-$450M (from the low end of the $450M-$530M initial range previously) while full-year 2013 revenue guidance was lowered to $3.4B-$3.6B (from $3.5B-$3.7B previously). We have reduced our EPS estimates from $3.30 to $3.15 in 2013, from $4.30 to $4.10 in 2014, and from $5.25 to $5.00 in 2015. Despite the lowered estimates, we reiterate our Buy rating on DRC and have increased our price target from $68 to $70 due to its strong and sustained long-term growth prospects across the energy value chain.”

IPC The Hospitalist Company closed on Friday at $60.74.

Latest Ratings for IPCM

DateFirmActionFromTo
Aug 2015JefferiesDowngradesBuyHold
Aug 2015DoughertyDowngradesNeutralSell
Aug 2015William BlairDowngradesOutperformMarket Perform

View More Analyst Ratings for IPCM
View the Latest Analyst Ratings

 

Related Articles (IPCM)

View Comments and Join the Discussion!

Posted-In: Citigroup Robin ShoemakerAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
AZOUBSMaintains1,250.0
AUBSMaintains87.0
NAVBHC Wainwright & Co.Maintains6.0
EDCFRAMaintains74.0
TNDMB of A SecuritiesMaintains95.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com